Neoadjuvant folfiri + bevacizumab in patients with resectable liver metastases from colo-rectal cancer: Results from a phase 2 trial and comparative analysis of early PET/CT scan vs recist criteria in predicting outcome. Issue 10 (October 2016) - Albino, V.; Izzo, F.; Palaia, R.; Di Giacomo, R.; Piccirillo, M.; Leongito, M.; Nasti, G.; Aloj, L.; Caracò, C.; Lastoria, S.